FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer’s Disease with Priority Review

NEXT STORY
Onconova Therapeutics to Provide Corporate Update and Second Quarter 2020 Earnings on August 12, 2020
PREV STORY
BioXcel Therapeutics to Host Second Quarter 2020 Operating and Financial Results Conference Call and Webcast
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ABVC BioPharma Reports Second Quarter 2021 Results

author_avatar
NASDAQ Market News

Collaborative Research by OpGen Group Company Ares Genetics and Johns Hopkins Researchers Demonstrates Potential of Next-Generation Sequencing for Investigation of Genetic Antimicrobial Resistance Mechanisms and Molecular Susceptibility Testing

author_avatar
NASDAQ Market News

Santhera to Present Novel Data Highlighting the Clinical Relevance of Peak Expiratory Flow as Predictor of Disease Progression in Duchenne Muscular Dystrophy

Pratteln, Switzerland, July 5, 2018 - Santhera Pharmaceuticals (SIX: SANN) announces that new data further supporting ...

author_avatar
NASDAQ Market News